Mary Caffrey

A joint session of ECTRIMS and the European Academy of Neurology assesses important topics in measuring relapse and progression in multiple sclerosis (MS).

Results for ozanimod, which is under review by FDA and European regulators for treatment of relapsing multiple sclerosis (MS), were presented in poster sessions September 12, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.

FDA recently accepted the Biologics Licensing Application for inebilizumab to treat a rare autoimmune condition, neuromyelitis optica spectrum disorder. The results for inebilizumab were presented at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.

Speakers at a session at ECTRIMS 2019 on long-term outcomes in multiple sclerosis said that better therapies and improved understanding of the effect of comorbidities have improved outcomes. The session was part of the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.

Maria Trojano, MD, professor of neurology at the University of Bari, Italy, offered the opening lecture at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.

A poster featuring a post-hoc exploratory analysis of measures of thalamic volume from RADIANCE was presented September 11, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.

Three studies published this year have examined the risks when patients with chronic pain abruptly stop taking opioids.

Dapagliflozin, sold by AstraZeneca as Farxiga, cut the risk of cardiovascular (CV) death and worsening of heart failure (HF) by 26% among patients with reduced ejection fraction alongside standard of care, according to results of a landmark phase 3 study presented Sunday at the European Society of Cardiology 2019 Congress. Results confirmed that the sodium glucose co-transporter 2 (SGLT2) inhibitor, already approved to treat type 2 diabetes (T2D), is just as effective in preventing CV death and HF events in patients who do not have T2D.

Data in the real-world study included a large share of patients over the age of 80, who are representative of those doctors see in clinical practice.

Diabetic retinopathy costs the United States $6.2 billion a year. Better screening techniques that can catch neurodegeneration at earlier stages have the potential to cut costs and improve quality of life for patients.

Coverage from the July 11, 2019, meeting of the Institute for Value-Based Medicine®, an initiative of The American Journal of Managed Care®. The meeting took place in Arlington, Virginia.

The findings suggest that a commonly used diabetes therapy, metformin, could be used to target specific proteins that trigger DNA repair.

Adding measurement of a key protein during metabolic assessment could help identify those at higher risk of heart attacks and strokes even if they have normal body mass index.

Studies on anticoagulants and SGLT2 inhibitors, and guidelines for dyslipidemia and more are anticipated at the meeting.

The findings suggest that all patients with monoclonal gammopathy of underdetermined significance should have annual blood testing to monitor whether risk of cancer change over time.

Findings appeared this month in the Journal of the American Academy of Dermatology.

Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure includes patients with and without type 2 diabetes, although the topline results did not specify if results were similar in these 2 populations.

Interest in omega-3 fatty acids have increased since publication of the results of REDUCE-IT.

Chronic pain, obesity and cancer, multiple myeloma patterns, pancreatic cancer screening updates, and more.

A Conversation With Barbara S. Levy, MD, Vice President, Health Policy, American College of Obstetricians and Gynecologists

The authors call for more personalized screening protocols to find cancer earlier in younger adults, as well as public health efforts to address obesity.

A review of the documentary on the life of James P. Allison, PhD, of The University of Texas MD Anderson Cancer Center, co-winner of the 2018 Nobel Prize in Physiology or Medicine.

A Conversation With Chief Medical Officer Andrew Norden, MD, MPH, MBA

The study's lead author said more work is needed to develop screening protocols for people who may face familial risk of a blood cancer.

The task force called for more research to develop better screening methods and work to decide if certain populations should be screened, such as those with diabetes.

Patients with chronic lymphocytic leukemia (CLL) will likely see a new standard of care based on outcomes in a phase 3 trial for patients treated with a combination of ibrutinib and rituximab.

CMS announced changes to make it easier for the consumer to know what they are paying for in healthcare and for physicians to manage chronic conditions.

The bill would reduce prices up to 75% based on anticipated 2020 levels, according to Senator Jeanne Shaheen, D-NH, the lead sponsor.

Unusual eating behavior can be seen in 70% of children who have autism, and it is so characteristic of this group that hypersensitivity to food textures or temperatures can be a reason for parents to look into an autism diagnosis, according to new research from Penn State College of Medicine.

The findings support 2017 guidelines from the American College of Cardiology and the American Heart Association to more aggressively treat high blood pressure.